PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells

The inhibition of epidermal growth factor receptor (EGFR) signaling by Gefitinib provides a promising treatment strategy for non-small cell lung cancer (NSCLC); however, drug resistance to Gefitinib and other tyrosine kinase inhibitors presents a major issue. Using NSCLC cell lines with differential...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xin-min, Pan, Shi-yun, Huang, Qi-ling, Lu, You-ni, Wu, Xiang-hua, Chang, Jian-Hua, Liu, Zhe-Bin, Cai, Xu-Wei, Liu, Qi, Wang, Jia-lei, Fu, Xiao-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226515/
https://www.ncbi.nlm.nih.gov/pubmed/27283902
http://dx.doi.org/10.18632/oncotarget.9891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226515/
https://www.ncbi.nlm.nih.gov/pubmed/27283902
http://dx.doi.org/10.18632/oncotarget.9891

Ejemplares similares